JP Patent
JP5567137B2 — Jak2阻害剤、ならびに骨髄増殖性疾患および癌の治療のためのそれらの使用
Assigned to Bristol Myers Squibb Co · Expires 2014-08-06 · 12y expired
What this patent protects
Patent listed against Calquence.
Drugs covered by this patent
- Calquence (ACALABRUTINIB) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.